Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Atea Pharmaceuticals and Xenon Pharmaceuticals: Two Clinical-Stage Firms That Rallied Instead of Crashing Yesterday

Two Clinical-Stage Firms Rallied Yesterday On a day when the Stock Market was crushed, taking down with it shareholders’ money for no reason other than the self-serving untouchable agendas, two small biotechnology companies staged rallies. Atea Pharmaceuticals and Xenon Pharmaceuticals...

October 5, 2021

Cytokinetics Product Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction

Cytokinetics Omecamtiv Mecarbil for Heat Failure Three biotech firms: Amgen ( AMGN ) , Cytokinetics ( CYTK ) and Servier worked on the Phase 3 GALACTIC-HF clinical trial to find out whether omecamtiv mecarbil, a product developed by the smallest of...

October 13, 2020

Denali Therapeutics: Positive Clinical Results and Regulatory Progress for Development Programs in ALS. See Also: NTLA Tumbling Today

Denali Therapeutics News Denali Therapeutics ( DNLI ) - a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ( BBB ) for neurodegenerative diseases. Denali pursues new treatments by rigorously assessing genetically validated...

October 8, 2021

A Great Game Changer for the History of Biotechnology

Intellia Therapeutics Scientific Co-Founder Shares Nobel Prize in Chemistry with Collaborator On October 07, 2020 Jennifer Doudna, Ph.D., one of Intellia Therapeutics ( NTLA ) scientific co-founders, was awarded the 2020 Nobel Prize in Chemistry for the development of the CRISPR/Cas9...

October 20, 2020

Gilead Sciences: The FDA Lifts Partial Clinical Hold on MDS and AML Magrolimab Studies. See Also: BioNTech

FDA Lifts Partial Clinical Hold on Gilead Sciences Studies of Magrolimab On April 12, 2022, Gilead Sciences ( GILD ) announced that the U.S. FDA lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination...

April 13, 2022

Interesting News from PTC Therapeutics and Arcturus Therapeutics Holdings

Arcturus Therapeutics Holdings News Arcturus Therapeutics Holdings ( ARCT ) shared topline data from an ongoing Phase 1/2/3 trial evaluating ARCT-154, Arcturus’ self-amplifying mRNA vaccine candidate against COVID-19. The ongoing Phase 1/2/3 registrational study, sponsored by Arcturus’ collaborator Vinbiocare Biotechnology...

April 20, 2022

Regenxbio Good News About RGX-314 for Diabetic Retinopathy

Regenxbio Announced Data from Phase 2 ALTITUDE Trial of RGX-314 for DR Regenxbio ( RGNX ) announced initial data from the ongoing Phase 2 ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy ( DR ) without center-involved diabetic...

October 11, 2021

Intellia Therapeutics and SparingVision Strategic Collaboration to Develop Novel Ocular Therapies. See Also: Crispr Therapeutics’ News is Good, Not Bad

Intellia Therapeutics and SparingVision Collaboration Intellia Therapeutics ( NTLA ) and SparingVision - a genomic medicine company developing vision saving treatments for ocular diseases, announced a strategic collaboration to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of...

October 14, 2021

Positive News for Two Undervalued Firms in the Prohost Portfolio

Exelixis CABOMETYX Approval Exelixis ( EXEL ) partner Ipsen received approval from the European Commission ( EC ) for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma ( DTC ), which is...

May 5, 2022

Rocket Pharmaceuticals Inc Announces Data Updates at the ESGCT Conference for RP-L201 for the Treatment of LAD-I

Rocket Pharmaceuticals Inc Announces Successful Results at the ESGCT Gene therapy and gene editing plus other gene and genome-based therapeutics are the only treatments expected to lead to miraculous cures. While genetic manipulation for the treatment of severe life-threatening diseases...

October 20, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024